NBIX
NEUROCRINE BIOSCIENCES INC
Nasdaq: NBIX · San Diego, CA · Healthcare
$130.22-1.37 (-1.04%)Closed
Market Cap$13.04B
Cash$1.08Bmost recent
Runwayprofitable
P/E (TTM)27.9EPS $4.67
52-Wk Range$98.95 – $160.18
Avg Volume1.2M3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$130.22-2.6%
Pipeline
Drug candidates sponsored by NEUROCRINE BIOSCIENCES · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 4 | Valbenazine | Tardive Dyskinesia (TD)+7 more | Recruiting | 2027-01 | 13 | |
| Phase 3 | NBI-34060 | Insomnia | Withdrawn | 2008-01past | 1 | |
| Phase 3 | NBI-98854 | Tardive Dyskinesia+1 more | Completed | 2019-02-18past | 10 | |
| Phase 3 | Placebo | Schizophrenia+4 more | Active, not recruiting | 2025-12past | 5 | |
| Phase 3 | NBI-1065845 | Major Depressive Disorder | Recruiting | 2027-07 | 5 | |
| Phase 3 | NBI-1117568 | Schizophrenia+2 more | Recruiting | 2027-10 | 6 | |
| Phase 3 | Crinecerfont | Congenital Adrenal Hyperplasia+1 more | Recruiting | 2028-03 | 5 | |
| Phase 3 | Indiplon | Insomnia+1 more | Terminated | — | 1 | |
| Phase 2 | interleukin-4 PE38KDEL cytotoxin | Brain and Central Nervous System Tumors+3 more | Completed | 2003-05past | 2 | |
| Phase 2 | TAK-831 | Friedreich Ataxia+2 more | Completed | 2019-06-09past | 4 | |
| Phase 2 | TAK-041 | Stable Schizophrenia+2 more | Completed | 2019-09-22past | 2 | |
| Phase 2 | NBI-74788 | CAH - Congenital Adrenal Hyperplasia | Completed | 2020-04-07past | 1 | |
| Phase 2 | Luvadaxistat | Schizophrenia | Completed | 2020-12-29past | 2 | |
| Phase 2 | NBI-827104 | Essential Tremor+2 more | Completed | 2025-01-27past | 3 | |
| Phase 2 | NBI-1070770 | Major Depressive Disorder | Completed | 2025-07-25past | 1 | |
| Phase 2 | NBI-921352 | SCN8A Developmental and Epileptic Encephalopathy Syndrome+2 more | Active, not recruiting | 2026-03past | 4 | |
| Phase 2 | NBI-1065890 | Tardive Dyskinesia | Not yet recruiting | 2027-02 | 1 | |
| Phase 2 | NBI-1117570 | Schizophrenia | Recruiting | 2027-08 | 1 | |
| Phase 2 | NBI-5788 | Multiple Sclerosis | Completed | — | 1 | |
| Phase 1 | NBI-6024 | Type 1 Diabetes Mellitus | Completed | 2006-04past | 1 | |
| Phase 1 | NBI-98854 50 mg capsule once daily | Effect of Ketoconazole on the PK of NBI-98854 in Healthy Subjects | Completed | 2013-08past | 1 | |
| Phase 1 | NBI-98854 50 mg capsule | Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects | Completed | 2013-12past | 1 | |
| Phase 1 | NBI-77860 | Congenital Adrenal Hyperplasia | Withdrawn | 2015-10past | 1 | |
| Phase 1 | TAK-831 Oral Suspension | Schizophrenia, Cerebellar Ataxia | Terminated | 2016-06-09past | 1 | |
| Phase 1 | Amphetamine | Healthy Volunteers | Completed | 2017-05-30past | 1 | |
| Phase 1 | TAK-653 Placebo | Depressive Disorder | Completed | 2017-09-11past | 1 | |
| Phase 1 | TAK-831 Tablet T2 | Healthy | Completed | 2018-09-09past | 1 | |
| Phase 1 | TAK-831 T2 | Healthy Volunteers | Completed | 2018-12-11past | 1 | |
| Phase 1 | TAK-653 | Healthy Volunteers | Completed | 2019-05-15past | 1 | |
| Phase 1 | TAK-831 Oral Tablet | Healthy Volunteers | Completed | 2020-04-04past | 1 | |
| Phase 1 | VY-AADC01 | Parkinson's Disease+8 more | Completed | 2021-08-10past | 2 | |
| Phase 1 | Opicapone | Parkinson Disease | Completed | 2022-08-04past | 2 | |
| Phase 1 | VY-AADC02 | Parkinson's Disease | Completed | 2024-10-30past | 1 | |
| N/A | Unnamed | Tardive Dyskinesia | Unknown | 2018-08past | 1 | |
| N/A | Unnamed | Parkinson's Disease | Completed | 2023-07-18past | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
No peer cohort defined for NBIX. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.